This article is more than 5 years old. Information may no longer be current.

DIABAMON: Risk for death, CV events now lower with diabetes medication

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — During the past several decades, diabetes medications appeared to decrease the risk for all-cause mortality and CV events in patients with the disease, according to data from the DIABAMON project presented here at the ADA Scientific Sessions.

Results from the DIABAMON project meta-analysis indicate that pioglitazone (Actos, Takeda) reduced the risk for death, MI and stroke (SRR=0.82; 95% CI, 0.72-0.94); metformin reduced the risk for CVD (SRR=0.85; 95% CI, 0.77-0.95); and insulin glargine (Lantus, Sanofi-Aventis) is not associated with an increased risk for CVD. However, studies have associated rosiglitazone (Avandia, GlaxoSmithKline) with an increased risk for CVD.

An analysis of clinical trials indicated that the death rate in patients with diabetes from all causes decreased from the 1970s (SRR=2.16; 95% CI, 1.87-2.48) through the 1980s (SRR=1.82; 95% CI, 1.69-1.96) and 1990s (SRR=1.69; 95% CI, 1.57-1.79). The SRR reached 1.89 (95% CI, 1.33-1.87) in the 2000s, according to the study abstract.

The data also indicated that the risk for death from CVD is decreasing, despite the research linking diabetes with a twofold increased risk for CVD. After examining the risk for CHD in patients with diabetes vs. those without the disease, researchers reported that the risk for patients recruited in the 1970s (SRR=2.27; 95% CI, 1.64-3.16) declined among those recruited in the 1980s (SRR=2.02; 95% CI, 1.78-2.29), the 1990s (SRR=1.98; 95% CI, 1.78-2.29) and 2000s (SRR=1.58; 95% CI, 1.66-2.37).

“Progress has been made in reducing the risk of major CVD and death in diabetes during the past 40 years,” researchers wrote. “There have been improvements in prevention prospects of CVD during the previous decades with the use of statins, better control of blood pressure and the trend to reduce tobacco smoking as well as better management of diabetes.” – by Alexandra Todak

For more information:

Boyle P. 1405-P. Presented at: ADA Scientific Sessions; June 21-25, 2013; Chicago.